About the Study

High-Risk Neuroblastoma (HRNBL): A Study of the Addition of Dinutuximab to Therapy

This study is being done for children and adults: • 30 years old or younger. • Diagnosed with High-Risk Neuroblastoma (HRNBL) The overall goal of this study is to compare the outcomes of dinutuximab given early with Induction therapy to the effects of standard Induction therapy with the addition of dinutuximab later in therapy in people with HRNBL to find out which is better.

Interested in learning more?

Full Study Name: ANBL2131 - A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma